SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, with community discussions focusing on potential support levels and whether this is a buying opportunity or the start of a deeper correction. Some traders attribute the price movement to liquidations and broader market factors, while others speculate about manipulation and the impact of macroeconomic events. The conversation includes both bullish and bearish perspectives, with some seeing it as a temporary dip and others anticipating further downside.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid discussions about ETF inflows and their potential impact on price, with some community members suggesting a possible supply squeeze.  Skeptics question XRP's ability to break free from Bitcoin's influence, while others remain optimistic about long-term gains, especially given upcoming events like the Flare Network activation.  Overall, the community is divided between those anticipating a breakout and those bracing for continued stagnation.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors eagerly await 48-week data and FDA meeting outcomes, key catalysts for Pemvidutide's development in MASH and obesity. The community is actively debating the potential for a buyout and strategic partnerships, focusing on the drug's differentiated profile and market opportunity. Community members are closely watching for signs of progress and discussing the implications of recent developments within the company and sector.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as investors debate its correlation to Bitcoin's price swings, especially after a recent dip in Bitcoin. The community is actively discussing whether MSTR is oversold and if a significant rebound is imminent, while others express concerns about potential forced selling and bankruptcy risks. There is also discussion around the stock's inclusion in the Nasdaq 100.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is trending as silver spot prices surge, sparking community discussion about a potential breakout. Many traders are pointing to a possible shift from crypto to precious metals, while others discuss the technicals with cup and handle formations and potential for long-term gains. Some investors are closely monitoring potential market manipulation and supply shortages.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as investors weigh its potential amid Bitcoin's volatility, with some traders noting its high short interest and potential for a squeeze. Community chatter reflects frustration with MARA's performance relative to peers, despite its significant Bitcoin holdings and pivot towards AI/HPC. Discussions also highlight concerns around management decisions and their impact on shareholder value.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending amidst a broader crypto market downturn, with traders closely watching key support levels and speculating on potential catalysts like the upcoming Fusaka upgrade. Community discussions revolve around bearish signals, possible further price drops, and whether this is a temporary pullback or a deeper correction. Some traders point to the broader macroeconomic environment and potential smart money rotation as factors influencing the price action.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to recent strategic partnerships and news from the DMCC Precious Metals Conference in Dubai, highlighting the adoption of its material-verification technology; the stock's low float has amplified volatility, fueling retail trader momentum, with the community debating whether it will reach $100 or face an imminent offering.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the crypto community discusses new ETF possibilities and their potential impact, with some anticipating a significant price surge independent of Bitcoin's movements. Community members are debating entry points and long-term prospects, while also weighing in on its performance relative to other cryptocurrencies. The launch of Bitwise DOGE ETF is on Wednesday, November 26.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as silver prices show strength, sparking community discussion about potential breakouts and new highs. Investors are weighing AG's potential against other silver miners, while anticipating earnings and Jerritt Canyon updates. Community members are actively debating optimal entry points, long-term prospects, and the impact of silver's increasing industrial and monetary value.

statis crypto Watchlist

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT

Intech Investment Management LLC lifted its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 102.9% during the second quarter, according to the company in its most recent Form 13F...

Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat...

Altimmune Target of Unusually Large Options Trading (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw some unusual options trading on Monday. Investors bought 11,978 call options on the company. This is an increase of 103% compared to the typical...

Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

<ul class="summary-bullets"><li>Retail traders focused on AI-driven biopsy findings and clearer dose-response&nbsp;exuded increased confidence in pemvidutide’s potential.</li><li>Analysts remained divided, with&nbsp;some citing strong MASH resolution and safety, while skeptics questioned differentiation and funding needs.</li><li>Lancet publication and AASLD late-breaker added momentum as Altimmune advanced additional liver-disease programs toward 2026 readouts.</li></ul>Retail discussion around Altimmune intensified over the weekend as investors looked ahead to the 48-week readout from the company’s IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), expected in the fourth quarter of 2025.&nbsp;<h2 class="st-heading-2">AI-Based Biopsy Analysis Adds Fresh Momentum</h2>Last week, Altimmune released results from an AI-based analysis of liver biopsies from the IMPACT Phase 2b trial. The company reported that 31% of patients in the 1.8 mg pemvidutide arm and 12% in the 1.2 mg arm achieved a 60% reduction in total fibrosis, compared with 8% for placebo. Improvements were also observed in early and advanced fibrosis categories, with reductions in the area of fibrosis exceeding 60% in select patient groups compared with placebo.Following the analysis, Citizens JMP lowered its price target to $14 and maintained an ‘Outperform’ rating,&nbsp;noting that&nbsp;it looked ahead to the late-breaking oral presentation at the Liver Meeting and the 48-week dataset expected this quarter. UBS maintained a ‘Buy’ rating, while Jefferies reiterated its ‘Buy’ recommendation, viewing pemvidutide as viable after meeting key histology endpoints at 24 weeks.<h2 class="st-heading-2">Mixed MASH Readout In July Still Shapes Sentiment</h2>Altimmune’s June and July update on its 24-week IMPACT&nbsp;Phase 2b results set the tone for the stock this year.&nbsp;The company reported that up to 59.1% of patients on pemvidutide achieved MASH resolution without worsening of fibrosis, compared to 19.1% for the placebo group. However, the endpoint of fibrosis improvement without worsening of MASH did not reach statistical significance.Despite this, the trial showed reductions in liver fat, inflammation and biomarkers of fibrosis, alongside meaningful weight loss, with up to 6.2% loss in treated patients compared with 1.0% for placebo. Safety remained favorable, with extremely low discontinuations and no drug-related serious adverse events.<h2 class="st-heading-2">Analyst Community Diverges Across The Year</h2>Bullish analysts’ optimism hinged on the drug’s early MASH resolution signal, weight loss trajectory and tolerability. UBS, Stifel, Jefferies and H.C. Wainwright all maintained ‘Buy’ ratings at various points, describing the 24-week results as either differentiated, fast-acting, viable for Phase 3 advancement or supportive of a potential best-in-class profile. Several of these firms highlighted AI-assisted fibrosis reads and non-invasive tests as consistent with anti-fibrotic activity.Others expressed more skepticism. In October, Citizens JMP cut its target earlier, while still keeping an ‘Outperform’ rating. Goldman Sachs resumed coverage with a ‘Sell’ rating, citing a lack of meaningful differentiation in obesity and MASH. Concerns about the company’s ability to fund a full Phase 3 program, especially after the mixed fibrosis outcome, were noted among analysts.<h2 class="st-heading-2">Peer-Reviewed Boost</h2>Last week, Altimmune said that The Lancet had published the 24-week efficacy and safety data from the IMPACT Phase 2b trial. The data were also selected for a late-breaking oral presentation at The Liver Meeting 2025 hosted by AASLD. Investigators highlighted significant MASH resolution, reductions in liver fat, anti-fibrotic signals and weight loss, reinforcing the drug’s potential to treat patients with moderate to advanced fibrosis.<h2 class="st-heading-2">Stocktwits Users See No ‘Breaks’ Ahead</h2>On Stocktwits, retail sentiment for Altimmune was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:972/139;" src="https://news.stocktwits-cdn.com/alt_ss_jpg_da81507313.webp" alt="alt ss.jpg" width="972" height="139"><figcaption>ALT sentiment and message volume as of November 16 | Source: Stocktwits</figcaption></figure>One user discussing the upcoming 48-week dataset pointed to the latest AASLD-published fibrosis odds-ratio findings and the clearer dose-response signals seen in the PathAI-derived analysis, suggesting these results strengthen the case for exploring a higher 2.4 mg dose aimed at accelerating fibrosis reduction, while keeping 1.8 mg and 1.2 mg positioned for broader cardiometabolic use and long-term maintenance.<stembedurl>https://stocktwits.com/BTECHINV/message/636410473</stembedurl>Another user said, “If 48 week MASH data is ‘BEST IN CLASS’ like the weight loss/muscle sparring data, we should get at least $15B for both…not to mention the other indications.”<stembedurl>https://stocktwits.com/Lazarus2024/message/636408646</stembedurl>A third user said, “48 week should confirm fibrosis improvement and we should race to 2 billion MC on it FAST. no breaks once it’s out.”<stembedurl>https://stocktwits.com/SuperPuncher/message/636408207</stembedurl><a href="https://stocktwits.com/symbol/ALT">Altimmune’s stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Equity

FY2025 EPS Estimates for Altimmune Boosted by HC Wainwright

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of Altimmune in a research note issued to investors on Tuesday...

Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29...

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT Altimmune, Inc. Securities Fraud Class Action Lawsuit...

Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect

ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning trade.Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease characterized by fat accumulation in the liver accompanied by inflammation and cell damage.The trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes. F2 and F3 fibrosis refer to stages of liver fibrosis, with F2 indicating moderate scarring and F3 indicating severe scarring.Up to 59.1% patients enrolled in the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-topline-results-impact-phase-2b">study</a> achieved MASH resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.However, the percentage of participants in the trial who achieved fibrosis improvement without worsening of MASH in an intent-to-treat analysis as compared to placebo was not statistically significant.Furthermore, only a total of 25.8% and 24.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, achieved the endpoint of both MASH resolution and fibrosis improvement, versus 13.5% in participants receiving placebo.Treatment with the drug, however, resulted in weight loss, with a mean weight loss of up to 6.2% in Pemvidutide-treated participants, compared to 1.0% in the placebo arm.Pemvidutide also demonstrated favorable safety and tolerability, with 0.0% and 1.2% adverse events (AE) related discontinuations in the pemvidutide 1.2 mg and 1.8 mg groups versus 2.4% in the placebo group, and there were no serious adverse events (SAEs) related to study medication, the company said.Scott Harris, Chief Medical Officer of Altimmune, expressed optimism about the company holding an end-of-mid-stage trial meeting with the FDA in the fourth quarter of 2025 and rapid progression to late-stage trials following the data.Pemvidutide is an investigational drug in development for the treatment of MASH, obesity, Alcohol Use Disorder (AUD), and Alcohol-associated Liver Disease (ALD).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALT">Altimmune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_26_at_8_59_53_AM_png_cf1065258b.webp" alt="ALT's Sentiment Meter and Message Volume as of 9:00 a.m. ET on June 26, 2025 | Source: Stocktwits" width="626" height="66"><figcaption>ALT's Sentiment Meter and Message Volume as of 9:00 a.m. ET on June 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that the fibrosis improvement data, which was the only thing “worth looking forward to”, was poor, and they see no ground to start a position.<stembedurl>https://stocktwits.com/Ag035/message/619068912</stembedurl>ALT stock is down by 54% this year and by 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-recalls-over-62000-silverado-trucks-in-us-over-fire-concerns/chmOVMWRR4j">General Motors Recalls Over 62,000 Silverado Trucks In US Over Fire Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Altimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A Position

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning trade.

Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALT News

ALTAltimmune Inc